References
- American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.
- Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the infectious disease society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18–55.
- Combes A, Luyt CE, Fagon JY, Wollf M, Trouillet JL, Gibert C, et al. Impact of methicillin resistance on outcome of Staphylococcus aureus ventilator-associated pneumonia. Am J Respir Crit Care Med. 2004;170:786–92.
- Shorr AF, Combes A, Kollef MH, Chastre J. Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy. Crit Care Med. 2006;34:700–6.
- Zahar JR, Clec’h C, Tafflet M, Garrouste-Oregeas M, Jamali S, Mourvillier B, et al. Is methicillin resistance associated with a worse prognosis in Staphylococcus aureus ventilator-associated pneumonia? Clin Infect Dis. 2005;41:1224–31.
- van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012;54(6):755–71.
- Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis. 2012;54(5):621–29.
- Steed ME, Rybak MJ. Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens. Pharmacotherapy. 2010;30:375–89.
- File TM Jr, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, double-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis. 2010;51(12):1395–405.
- Lobo LJ, Reed KD, Wunderink RG. Expanded clinical presentation of community-acquired methicillin-resistant Staphylococcus aureus pneumonia. Chest. 2010;138(1):130–6.
- Forest Laboratories Inc. Teflaro prescribing information. St. Louis, MO, USA: Forest Laboratories Inc; 2012.
- Clinical Trials.gov. Evaluation of ceftaroline fosamil versus a comparator in adult subjects with community-acquired bacterial pneumonia (CABP) with risk for methicillin-resistant Staphylococcus aureus. Clinical trials.gov identifier: NCT01645735. http://www.clinicaltrials.gov (accessed 2013 January 14).
- Farrell DJ, Castanheira M, Mendes RE, Sader HS, Jones RN. In Vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumonia: a review of published studies and the AWARE surveillance program (2008–2010). Clin Infect Dis. 2012;55(S3):S206–14.
- Vidaillac C, Leonard SN, Rybak MJ. In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired methicillin-resistant Staphylococcus aureus (HA-MRSA) isolates. Int J Antimicrob Agents. 2010;35:527–30.
- Bhalodi AA, Crandon JL, Biek D, Nicolau DP. Efficacy of ceftaroline fosamil in a Staphylococcal murine pneumonia model. Antimicrob Agents Chemother. 2012;56(12):6160–5.